Tirzepatide vs Semaglutide: Head-to-Head Data

Summary

This is the only major incretin comparison supported by direct head-to-head trials. SURPASS-2 compared the two in type 2 diabetes and SURMOUNT-5 in obesity, both reporting greater weight reduction with tirzepatide. Semaglutide, however, has the longer cardiovascular outcome record.

Last reviewed 2026-09-01

What it is

A comparison of semaglutide, a GLP-1 receptor agonist, with tirzepatide, a GIP/GLP-1 dual receptor agonist, based on trials that randomised participants to both.

Semaglutide reached obesity indications through the STEP programme from 2021; tirzepatide followed through SURMOUNT. SURPASS-2 (2021) and SURMOUNT-5 (2025) provided the direct comparisons.

Both are synthetic, long-acting incretin analogues designed for weekly administration.

It is the rare case in this field where a comparison rests on randomised head-to-head data rather than cross-trial arithmetic.

How it works

In plain terms

Semaglutide acts on one gut hormone receptor; tirzepatide acts on two. The second receptor appears to add weight reduction, though the reason is still debated.

Technical detail

Semaglutide is a GLP-1 receptor agonist with albumin-binding fatty acid modification giving a roughly one-week half-life. Tirzepatide additionally activates the GIP receptor, with higher affinity for GIPR than GLP-1R. The contribution of GIP receptor activity is mechanistically contested: both agonism and antagonism of GIPR have shown weight benefit in different models, and adipose GIPR signalling plus central effects are proposed explanations. Both slow gastric emptying, enhance glucose-dependent insulin secretion and reduce appetite centrally.

Pathways involved

GLP-1R agonism: satiety, gastric emptying, insulinotropic effect
GIPR agonism (tirzepatide): adipose and central contributions
Albumin-binding acylation for weekly dosing

Current research

Laboratory research

Receptor binding and signalling bias profiles are published for both.

Animal research

Dual agonism outperformed GLP-1 monotherapy on weight endpoints in rodent models at matched exposures.

Human research

SURPASS-2 randomised people with type 2 diabetes to tirzepatide or semaglutide 1 mg, reporting greater HbA1c and weight reduction with tirzepatide at all three doses. SURMOUNT-5 compared tirzepatide with semaglutide 2.4 mg in obesity without diabetes and reported approximately 20.2% versus 13.7% mean weight reduction at 72 weeks. Semaglutide holds cardiovascular outcome evidence from SELECT, which reported a 20% reduction in major adverse cardiovascular events in people with obesity and established cardiovascular disease; tirzepatide's equivalent outcome data is still maturing.

Ongoing research

Tirzepatide cardiovascular and outcome trials continue to report.

What is being investigated

Relative weight and glycaemic efficacy
The mechanistic contribution of GIP receptor activity
Tolerability and discontinuation rates at comparable doses
Cardiovascular and organ-specific outcomes beyond weight

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

Greater weight reduction is not the same as a better outcome profile — SELECT gives semaglutide the stronger outcome record so far
Gastrointestinal adverse events were common with both in head-to-head trials
SURPASS-2 used semaglutide 1 mg, a diabetes dose lower than the 2.4 mg obesity dose
Weight regain after discontinuation is documented for both
Muscle mass loss within total weight loss is inadequately characterised for both

Evidence ratings

Head-to-head human data

Strong

SURPASS-2 and SURMOUNT-5 randomised direct comparisons.

Semaglutide outcome data

Strong

SELECT cardiovascular outcome trial.

Tirzepatide outcome data

Moderate

Outcome programmes still maturing.

GIPR mechanism

Limited

Contribution of GIPR agonism remains contested.

Comparisons

Retatrutide vs tirzepatide

No head-to-head data exists there.

Cagrilintide vs semaglutide

Amylin versus incretin mechanism.

References

[1]SURPASS-2 head-to-head trial — PubMed / NEJM, 2021
[2]SURMOUNT-5 head-to-head obesity trial — PubMed / NEJM, 2025
[3]SELECT cardiovascular outcomes trial — PubMed / NEJM, 2023
Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

Which produced more weight loss?+

Tirzepatide, in both SURPASS-2 and SURMOUNT-5, with roughly 20.2% versus 13.7% mean reduction at 72 weeks in SURMOUNT-5.

Is tirzepatide therefore better?+

Not straightforwardly. Semaglutide has stronger cardiovascular outcome evidence from SELECT, and outcomes matter beyond weight.

What is SURMOUNT-5?+

A randomised head-to-head obesity trial comparing tirzepatide with semaglutide 2.4 mg over 72 weeks.

Why did SURPASS-2 use semaglutide 1 mg?+

It was a type 2 diabetes trial, and 1 mg was the approved diabetes dose at the time — lower than the obesity dose.

Does GIP receptor activation explain the difference?+

Probably in part, but the mechanism is contested: both GIPR agonism and antagonism have shown weight benefit in different models.

What did SELECT show?+

A roughly 20% reduction in major adverse cardiovascular events with semaglutide in people with obesity and established cardiovascular disease.

Are side effects different?+

Both cause dose-related gastrointestinal effects; head-to-head trials did not show a large tolerability separation.

Does weight return after stopping?+

Substantial regain after discontinuation is documented for both agents.

Continue your research

Semaglutide research

Tirzepatide research

Incretin side effects